{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:04:05Z","timestamp":1789005845073,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015731","name":"Bayer yakuhin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The overactivation of mineralocorticoid receptor (MR) plays a key pathological role in the progression of cardiovascular and renal diseases by promoting pro-inflammatory and pro-fibrotic signaling. Recently, it has been found that finerenone, a novel nonsteroidal selective MR antagonist, can robustly improve cardiorenal outcomes in patients with type 2 diabetes (T2D) and a wide spectrum of chronic kidney disease (CKD). However, the mechanisms underlying the cardiorenal benefits of finerenone are poorly understood. Further, whether the clinical benefits are mediated by an improvement in vascular stiffness is not confirmed. Therefore, the current study aims to evaluate the effects of finerenone on vascular stiffness as assessed using cardio ankle vascular index (CAVI) and relevant cardiorenal biomarkers in patients with T2D and CKD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Effects of <jats:underline>Fi<\/jats:underline>nerenone on <jats:underline>V<\/jats:underline>ascular Stiffn<jats:underline>e<\/jats:underline>ss and Cardiorenal Biomarker<jats:underline>s<\/jats:underline> in <jats:underline>T<\/jats:underline>ype 2 Di<jats:underline>a<\/jats:underline>betes and Ch<jats:underline>r<\/jats:underline>onic Kidney Disease (FIVE-STAR) is an ongoing, investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized clinical trial in Japan. Its target sample size is 100 subjects. Recruitment will be performed from September 2023 to July 2024. After obtaining informed consent, eligible participants with T2D and CKD (25\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>\u2009\u2264\u2009estimated glomerular filtration ratio [eGFR]\u2009&lt;\u200990\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup> and 30\u00a0mg\/g Cr\u2009\u2264\u2009urinary albumin-to-creatinine ratio [UACR]\u2009&lt;\u20093500 mg\/g Cr) will be equally randomized to receive 24-week treatment with either finerenone (starting dose at 10 mg once daily in participants with a baseline eGFR\u2009&lt;\u200960\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup> or at 20 mg once daily in those with a baseline eGFR\u2009\u2265\u200960 mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>) or dose-matched placebo. The primary endpoint is the change from baseline in CAVI at 24 weeks. The secondary endpoints are changes from baseline in UACR at 12 and 24 weeks and relevant serum and urinary biomarkers at 24 weeks. As an exploratory endpoint, proteomic analysis using the Olink\u00ae Target 96 panels will be also performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>FIVE-STAR is the first trial evaluating the therapeutic impact of finerenone on vascular stiffness and relevant cardiorenal biomarkers in patients with T2D and CKD. This study will provide mechanistic insights on the clinical benefits of finerenone based on recent cardiovascular and renal outcome trials.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Unique Trial Number, NCT05887817 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05887817\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05887817<\/jats:ext-link>) and jRCTs021230011 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/jrct.niph.go.jp\/latest-detail\/jRCTs021230011\">https:\/\/jrct.niph.go.jp\/latest-detail\/jRCTs021230011<\/jats:ext-link>).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01928-y","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T16:03:19Z","timestamp":1690819399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR)"],"prefix":"10.1186","volume":"22","clinical-trial-number":[{"clinical-trial-number":"nct05887817","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Atsushi","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisako","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoaki","family":"Miyazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiju","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Teragawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Moroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the FIVE-STAR trial investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"issue":"3","key":"1928_CR1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jdi.13355","volume":"12","author":"H Li","year":"2021","unstructured":"Li H, Lu W, Wang A, Jiang H, Lyu J. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from Global burden of disease 2017. J Diabetes Investig. 2021;12(3):346\u201356.","journal-title":"J Diabetes Investig"},{"issue":"3","key":"1928_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/dom.14601","volume":"24","author":"A Chaudhuri","year":"2022","unstructured":"Chaudhuri A, Ghanim H, Arora P. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes Obes Metab. 2022;24(3):365\u201376.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1928_CR3","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, Rosas SE, Rossing P, Bakris G. Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO). Kidney Int. 2022;102(5):974\u201389.","journal-title":"Kidney Int"},{"issue":"24","key":"1928_CR4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"1928_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"1928_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"1928_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7326\/M22-2904","volume":"176","author":"SD Navaneethan","year":"2023","unstructured":"Navaneethan SD, Zoungas S, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Liew A, Michos ED, Olowu WA, Sadusky T, et al. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023;176(3):381\u20137.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1928_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","volume":"96","author":"J Barrera-Chimal","year":"2019","unstructured":"Barrera-Chimal J, Girerd S, Jaisser F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int. 2019;96(2):302\u201319.","journal-title":"Kidney Int"},{"issue":"5","key":"1928_CR9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ajh.2011.245","volume":"25","author":"H Shibata","year":"2012","unstructured":"Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25(5):514\u201323.","journal-title":"Am J Hypertens"},{"issue":"1","key":"1928_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","volume":"17","author":"G Currie","year":"2016","unstructured":"Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, Boesby L, Edwards NC, Ferro CJ, Townend JN, et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016;17(1):127.","journal-title":"BMC Nephrol"},{"issue":"18","key":"1928_CR11","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u20131032.","journal-title":"Circulation"},{"issue":"8","key":"1928_CR12","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L B\u00e4rfacker","year":"2012","unstructured":"B\u00e4rfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-P\u00e9rez S, Heckroth H, Nitsche A, Erg\u00fcden JK, Gielen-Haertwig H, Schlemmer KH, et al. Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385\u2013403.","journal-title":"ChemMedChem"},{"issue":"23","key":"1928_CR13","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"1928_CR14","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"issue":"6","key":"1928_CR15","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"issue":"4","key":"1928_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.5551\/jat.5983","volume":"18","author":"KJ Kim","year":"2011","unstructured":"Kim KJ, Lee BW, Kim HM, Shin JY, Kang ES, Cha BS, Lee EJ, Lim SK, Lee HC. Associations between cardio-ankle vascular index and microvascular complications in type 2 diabetes mellitus patients. J Atheroscler Thromb. 2011;18(4):328\u201336.","journal-title":"J Atheroscler Thromb"},{"issue":"9","key":"1928_CR17","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1097\/HJH.0000000000000651","volume":"33","author":"K Hayashi","year":"2015","unstructured":"Hayashi K, Yamamoto T, Takahara A, Shirai K. Clinical assessment of arterial stiffness with cardio-ankle vascular index: theory and applications. J Hypertens. 2015;33(9):1742\u201357 (discussion 1757).","journal-title":"J Hypertens"},{"issue":"5","key":"1928_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.5551\/jat.44834","volume":"26","author":"K Takahashi","year":"2019","unstructured":"Takahashi K, Yamamoto T, Tsuda S, Okabe F, Shimose T, Tsuji Y, Suzuki K, Otsuka K, Takata M, Shimizu K, et al. Coefficients in the CAVI equation and the comparison between CAVI with and without the coefficients using clinical data. J Atheroscler Thromb. 2019;26(5):465\u201375.","journal-title":"J Atheroscler Thromb"},{"issue":"8","key":"1928_CR19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jchf.2021.02.016","volume":"9","author":"NH Brandt-Jacobsen","year":"2021","unstructured":"Brandt-Jacobsen NH, Lav Madsen P, Johansen ML, Rasmussen JJ, Forman JL, Holm MR, Rye J\u00f8rgensen N, Faber J, Rossignol P, Schou M, et al. Mineralocorticoid receptor antagonist improves cardiac structure in type 2 diabetes: data from the MIRAD trial. JACC Heart Fail. 2021;9(8):550\u20138.","journal-title":"JACC Heart Fail"},{"issue":"12","key":"1928_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.5551\/jat.29926","volume":"22","author":"SL Chung","year":"2015","unstructured":"Chung SL, Yang CC, Chen CC, Hsu YC, Lei MH. Coronary artery calcium score compared with cardio-ankle vascular index in the prediction of cardiovascular events in asymptomatic patients with type 2 diabetes. J Atheroscler Thromb. 2015;22(12):1255\u201365.","journal-title":"J Atheroscler Thromb"},{"issue":"11","key":"1928_CR21","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1097\/HJH.0000000000001437","volume":"35","author":"P Wohlfahrt","year":"2017","unstructured":"Wohlfahrt P, C\u00edfkov\u00e1 R, Movsisyan N, Kunzov\u00e1 \u0160, Le\u0161ovsk\u00fd J, Homolka M, So\u0161ka V, Dob\u0161\u00e1k P, Lopez-Jimenez F, Sochor O. Reference values of cardio-ankle vascular index in a random sample of a white population. J Hypertens. 2017;35(11):2238\u201344.","journal-title":"J Hypertens"},{"issue":"2","key":"1928_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/ehjcvp\/pvac059","volume":"9","author":"A Tanaka","year":"2023","unstructured":"Tanaka A, Sata M, Okada Y, Teragawa H, Eguchi K, Shimabukuro M, Taguchi I, Matsunaga K, Kanzaki Y, Yoshida H, et al. Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial. Eur Heart J Cardiovasc Pharmacother. 2023;9(2):165\u201372.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"1928_CR23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","volume":"9","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2021","unstructured":"Requena-Ib\u00e1\u00f1ez JA, Santos-Gallego CG, Rodriguez-Cordero A, Vargas-Delgado AP, Mancini D, Sartori S, Atallah-Lajam F, Giannarelli C, Macaluso F, Lala A, et al. Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study. JACC Heart Fail. 2021;9(8):578\u201389.","journal-title":"JACC Heart Fail"},{"issue":"9","key":"1928_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jdiacomp.2019.05.009","volume":"33","author":"C Zhang","year":"2019","unstructured":"Zhang C, Zhong Y, Tian H. Increased cardio-ankle vascular index is independently associated with chronic kidney disease: a cross-sectional study in Chinese patients with type 2 diabetes mellitus. J Diabetes Complications. 2019;33(9):623\u20137.","journal-title":"J Diabetes Complications"},{"issue":"5","key":"1928_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bcp.14194","volume":"86","author":"CE Mills","year":"2020","unstructured":"Mills CE, Govoni V, Faconti L, Casagrande ML, Morant SV, Crickmore H, Iqbal F, Maskell P, Masani A, Nanino E, et al. A randomised, factorial trial to reduce arterial stiffness independently of blood pressure: proof of concept? The VaSera trial testing dietary nitrate and spironolactone. Br J Clin Pharmacol. 2020;86(5):891\u2013902.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1928_CR26","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/HJH.0000000000001989","volume":"37","author":"S Kishimoto","year":"2019","unstructured":"Kishimoto S, Oki K, Maruhashi T, Kajikawa M, Matsui S, Hashimoto H, Takaeko Y, Kihara Y, Chayama K, Goto C, et al. Eplerenone improves endothelial function and arterial stiffness and inhibits Rho-associated kinase activity in patients with idiopathic hyperaldosteronism: a pilot study. J Hypertens. 2019;37(5):1083\u201395.","journal-title":"J Hypertens"},{"issue":"4","key":"1928_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jchf.2020.11.010","volume":"9","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ, Brunner-La-Rocca HP, Clark AL, Cosmi F, Cuthbert J, et al. Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC Heart Fail. 2021;9(4):268\u201377.","journal-title":"JACC Heart Fail"},{"issue":"48","key":"1928_CR28","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","volume":"43","author":"F Zannad","year":"2022","unstructured":"Zannad F, Ferreira JP, Butler J, Filippatos G, Januzzi JL, Sumin M, Zwick M, Saadati M, Pocock SJ, Sattar N, et al. Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme. Eur Heart J. 2022;43(48):4991\u20135002.","journal-title":"Eur Heart J"},{"issue":"18","key":"1928_CR29","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, Dixon DL, Januzzi JL Jr, Yancy CW. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2023;81(18):1835\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1928_CR30","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/ndt\/gfab336","volume":"37","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Boletis J, Toto R, Umpierrez GE, Wanner C, et al. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. 2022;37(7):1261\u20139.","journal-title":"Nephrol Dial Transplant"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01928-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T16:04:41Z","timestamp":1690819481000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01928-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1928"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01928-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]},"assertion":[{"value":"5 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Certified Review Board of Fukushima Medical University (no. F2023001). The study is now conducted in accordance with the Declaration of Helsinki and the Clinical Trial Act in Japan. After the patients are initially screened for eligibility based on their prior medical records, they will receive adequate explanations about the trial plan before they provide a written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AT received honoraria from Boehringer Ingelheim and research funding from GlaxoSmithKline, Takeda, Bristol-Myers Squibb and Novo Nordisk. HS has received speaking fees from Bayer, Daiichi Sankyo, AstraZeneca, and Novartis Pharma and scholarship from Bayer and Chugai Pharmaceutical. TI received lecture fees from JCR Pharmaceuticals and Kyowa Kirin. HY reported receiving lecture fee from Kyowa Kirin. MMiyazono has received honoraria from Chugai Pharmaceutical, Astellas, Kyowa Kirin, Mitsubishi Tanabe, Mochida Pharmaceutical, AstraZeneca, Bayer Yakuhin, Torii Pharmaceutical, Fuso Pharmaceutical Industries, Teijin Pharma, and Kissei Pharmaceutical, research grant from Chugai Pharmaceutical, and scholarship from Kyowa Kirin, Torii Pharmaceutical, Fuso Pharmaceutical Industries, and Kissei Pharmaceutical. NT received honoraria from Daiichi Sankyo, Novartis Pharma, Boehringer Ingelheim, Toa Eiyo, Bristol Myers Squibb, Pfizer, AstraZeneca, and Bayer Yakuhin. DF has received honoraria from Bayer Yakuhin, Daiichi Sankyo, and Otsuka Pharmaceutical. HT received research grants from AstraZeneca, Daiichi Sankyo, Janssen, Novo Nordisk, and Eli Lilly. KK received honoraria from AstraZeneca, Ono Pharmaceutical, Boehringer Ingelheim, Otsuka Pharmaceutical, and Novartis Pharma. MMoroi has received honoraria from Takeda, Sanofi, Bayer, Otsuka Pharmaceutical, Mitsubishi Tanabe, and Amicus Therapeutics and research grant from Teijin Pharma, Sanofi, Nihon Medi-physics, and Amicus Therapeutics. ST received honoraria from Otsuka Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo, Bayer Yakuhin, AstraZeneca, and Novartis Pharma. MS has received speaker's honoraria from Bayer Yakuhin. KT has received honoraria from Abbott Medical, Boston Scientific, Orbusneich, Kaneka, Japan Lifeline, Edwards Lifesciences, HeatFlow, Bayer Yakuhin, Medis, and Daiichi Sankyo. MN has received lecture fees from Kyowa Kirin, Astellas, GlaxoSmithKline, Daiichi Sankyo, Mitsubishi Tanabe, Chugai Pharmaceutical, Torii Pharmaceutical, JT, Alexion, Akebia, MSD, and Boehringer Ingelheim and research support from JT, Kyowa Kirin, Astellas, Ono Pharmaceutical, Takeda, Daiichi Sankyo, Mitsubishi Tanabe, Chugai Pharmaceutical, Torii Pharmaceutical, Kissei Pharmaceutical, and Boehringer Ingelheim. KN has received honoraria from AstraZeneca, Bayer Yakuhin, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe, MSD, Novartis Pharma, Novo Nordisk, Ono Pharmaceutical, Otsuka Pharmaceutical, and Takeda, research grant from Asahi Kasei, Astellas, Boehringer Ingelheim, Fuji Yakuhin, Mitsubishi Tanabe, Mochida Pharmaceutical, Novartis Pharma, and Teijin Pharma, and Scholarship from Bayer Yakuhin, Medtronic, Teijin Pharma. AT and KN are Editorial Board members of the journal, and they were not involved in handling this manuscript during the submission and the review processes. Other authors declare no potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}